Doxa AB (publ) (DOXA.ST)
SEK 0.35
(-1.82%)
SEK 0.35
(-1.82%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.75 Billion SEK | 110.05% |
| 2022 | 1.78 Billion SEK | 103.41% |
| 2021 | 878.8 Million SEK | 5969.9% |
| 2020 | 14.47 Million SEK | -12.92% |
| 2019 | 16.62 Million SEK | -42.24% |
| 2018 | 28.78 Million SEK | 26.68% |
| 2017 | 22.72 Million SEK | 57.68% |
| 2016 | 14.41 Million SEK | -25.79% |
| 2015 | 19.41 Million SEK | -21.09% |
| 2014 | 24.6 Million SEK | 99.49% |
| 2013 | 12.33 Million SEK | -30.01% |
| 2012 | 17.62 Million SEK | -50.95% |
| 2011 | 35.93 Million SEK | -24.44% |
| 2010 | 47.55 Million SEK | 66.86% |
| 2009 | 28.49 Million SEK | -6.24% |
| 2008 | 30.39 Million SEK | -1.41% |
| 2007 | 30.83 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.49 Billion SEK | 6.34% |
| 2024 Q1 | 3.28 Billion SEK | -12.52% |
| 2023 Q4 | 3.75 Billion SEK | 10.75% |
| 2023 Q3 | 3.39 Billion SEK | 19.5% |
| 2023 Q2 | 2.83 Billion SEK | 61.03% |
| 2023 Q1 | 1.76 Billion SEK | -1.44% |
| 2023 FY | 3.75 Billion SEK | 110.05% |
| 2022 Q1 | 1.86 Billion SEK | 111.75% |
| 2022 FY | 1.78 Billion SEK | 103.41% |
| 2022 Q3 | 1.88 Billion SEK | 0.0% |
| 2022 Q4 | 1.78 Billion SEK | -5.35% |
| 2022 Q2 | 1.88 Billion SEK | 1.49% |
| 2021 Q2 | 91.7 Million SEK | 639.52% |
| 2021 FY | 878.8 Million SEK | 5969.9% |
| 2021 Q3 | 203.7 Million SEK | 122.14% |
| 2021 Q4 | 878.8 Million SEK | 331.42% |
| 2021 Q1 | 12.4 Million SEK | -14.35% |
| 2020 Q4 | 14.47 Million SEK | 11.37% |
| 2020 Q3 | 13 Million SEK | -21.21% |
| 2020 Q2 | 16.5 Million SEK | -6.25% |
| 2020 Q1 | 17.6 Million SEK | 5.86% |
| 2020 FY | 14.47 Million SEK | -12.92% |
| 2019 Q3 | 16.8 Million SEK | -17.24% |
| 2019 Q4 | 16.62 Million SEK | -1.04% |
| 2019 FY | 16.62 Million SEK | -42.24% |
| 2019 Q1 | 27 Million SEK | -6.2% |
| 2019 Q2 | 20.3 Million SEK | -24.81% |
| 2018 Q3 | 30.9 Million SEK | -6.93% |
| 2018 Q4 | 28.78 Million SEK | -6.85% |
| 2018 Q2 | 33.2 Million SEK | 82.42% |
| 2018 FY | 28.78 Million SEK | 26.68% |
| 2018 Q1 | 18.2 Million SEK | -19.9% |
| 2017 Q2 | 11.1 Million SEK | -26.49% |
| 2017 Q1 | 15.1 Million SEK | 4.79% |
| 2017 FY | 22.72 Million SEK | 57.68% |
| 2017 Q3 | 10.6 Million SEK | -4.5% |
| 2017 Q4 | 22.72 Million SEK | 114.35% |
| 2016 Q3 | 13.2 Million SEK | -6.38% |
| 2016 FY | 14.41 Million SEK | -25.79% |
| 2016 Q4 | 14.41 Million SEK | 9.17% |
| 2016 Q2 | 14.1 Million SEK | -12.96% |
| 2016 Q1 | 16.2 Million SEK | -16.57% |
| 2015 FY | 19.41 Million SEK | -21.09% |
| 2015 Q3 | 12.2 Million SEK | -27.81% |
| 2015 Q2 | 16.9 Million SEK | -19.91% |
| 2015 Q1 | 21.1 Million SEK | -14.25% |
| 2015 Q4 | 19.41 Million SEK | 59.16% |
| 2014 FY | 24.6 Million SEK | 99.49% |
| 2014 Q4 | 24.6 Million SEK | 146.07% |
| 2014 Q3 | 10 Million SEK | -28.06% |
| 2014 Q2 | 13.9 Million SEK | -30.85% |
| 2014 Q1 | 20.1 Million SEK | 62.95% |
| 2013 Q4 | 12.33 Million SEK | 0.29% |
| 2013 Q3 | 12.29 Million SEK | -23.89% |
| 2013 FY | 12.33 Million SEK | -30.01% |
| 2013 Q2 | 16.15 Million SEK | 0.0% |
| 2012 Q4 | 17.62 Million SEK | 0.0% |
| 2012 FY | 17.62 Million SEK | -50.95% |
| 2011 FY | 35.93 Million SEK | -24.44% |
| 2010 FY | 47.55 Million SEK | 66.86% |
| 2009 FY | 28.49 Million SEK | -6.24% |
| 2008 FY | 30.39 Million SEK | -1.41% |
| 2007 FY | 30.83 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AddLife AB (publ) | 12.74 Billion SEK | 70.539% |
| Biotage AB (publ) | 4.93 Billion SEK | 23.853% |
| Bonesupport Holding AB (publ) | 688.81 Million SEK | -445.109% |
| Elekta AB (publ) | 31.41 Billion SEK | 88.047% |
| iZafe Group AB (publ) | 34.61 Million SEK | -10747.634% |
| Ortivus AB (publ) | 72.7 Million SEK | -5064.361% |
| Ortivus AB (publ) | 72.7 Million SEK | -5064.361% |
| Q-linea AB (publ) | 231.97 Million SEK | -1518.616% |
| S2Medical AB (publ) | 21.4 Million SEK | -17439.722% |
| Synsam AB (publ) | 8.03 Billion SEK | 53.275% |